Quince Therapeutics, Inc. Financing Cash Flow
Quince Therapeutics, Inc. (QNCX) reported Financing Cash Flow of $118.38 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-14
- Quince Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $108.93M, a 655.85% increase year-over-year.
- Quince Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $9.44M, a 10754.02% increase year-over-year.
- Quince Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $2.03M.
- Quince Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $1.38M.
- Quince Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $17.91M.
- Quince Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2024 was -$4.78M, a 3439.16% decline from fiscal 2023.
- Quince Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $143.00K, a 79.77% decline from fiscal 2022.
- Quince Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $707.00K, a 89.62% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $108.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $118.38M 10-Q · filed 2026-08-14 | $120.41M derived: sum of 3 quarters · filed 2026-08-14 | $121.79M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $9.44M 10-Q · filed 2026-05-11 | $11.48M derived: sum of 2 quarters · filed 2026-05-11 | $12.85M derived: sum of 3 quarters · filed 2026-05-11 | $27.27M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $2.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $3.41M derived: sum of 2 quarters · filed 2026-04-10 | $17.82M derived: sum of 3 quarters · filed 2026-08-14 | $17.91M 10-K · filed 2026-04-10 |
| 2025-09-30 | $1.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $15.79M derived: sum of 2 quarters · filed 2026-08-14 | $15.88M 10-Q · filed 2025-11-12 | $15.88M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $14.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $14.50M 10-Q · filed 2026-08-14 | $14.50M derived: sum of 3 quarters · filed 2026-08-14 | $9.50M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $87.00K 10-Q · filed 2026-05-11 | $87.00K derived: sum of 2 quarters · filed 2026-05-11 | -$4.91M derived: sum of 3 quarters · filed 2026-05-11 | -$4.88M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | -$5.00M derived: sum of 2 quarters · filed 2026-04-10 | -$4.96M derived: sum of 3 quarters · filed 2026-04-10 | -$4.78M 10-K · filed 2026-04-10 |
| 2024-09-30 | -$5.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$4.96M derived: sum of 2 quarters · filed 2025-11-12 | -$4.78M 10-Q · filed 2025-11-12 | -$4.72M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $35.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $225.00K 10-Q · filed 2025-08-11 | $282.00K derived: sum of 3 quarters · filed 2025-08-11 | $292.00K derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $190.00K 10-Q · filed 2025-05-13 | $247.00K derived: sum of 2 quarters · filed 2025-05-13 | $257.00K derived: sum of 3 quarters · filed 2025-05-13 | $283.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $57.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $67.00K derived: sum of 2 quarters · filed 2025-03-24 | $93.00K derived: sum of 3 quarters · filed 2025-03-24 | $143.00K 10-K · filed 2025-03-24 |
| 2023-09-30 | $10.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $36.00K derived: sum of 2 quarters · filed 2024-11-13 | $86.00K 10-Q · filed 2024-11-13 | $68.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $26.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $76.00K 10-Q · filed 2024-08-13 | $58.00K derived: sum of 3 quarters · filed 2024-08-13 | $53.00K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $50.00K 10-Q · filed 2024-05-13 | $32.00K derived: sum of 2 quarters · filed 2024-05-13 | $27.00K derived: sum of 3 quarters · filed 2024-05-13 | $135.00K derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | -$18.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$23.00K derived: sum of 2 quarters · filed 2024-04-01 | $85.00K derived: sum of 3 quarters · filed 2024-04-01 | $707.00K 10-K · filed 2024-04-01 |
| 2022-09-30 | -$5.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $103.00K derived: sum of 2 quarters · filed 2023-11-14 | $725.00K 10-Q · filed 2023-11-14 | $1.72M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $108.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $730.00K 10-Q · filed 2023-08-03 | $1.72M derived: sum of 3 quarters · filed 2023-08-03 | $6.42M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $622.00K 10-Q · filed 2023-05-15 | $1.61M derived: sum of 2 quarters · filed 2023-05-15 | $6.32M derived: sum of 3 quarters · filed 2023-05-15 | $6.99M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | $990.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $5.70M derived: sum of 2 quarters · filed 2023-03-15 | $6.37M derived: sum of 3 quarters · filed 2023-03-15 | $6.81M 10-K · filed 2023-03-15 |
| 2021-09-30 | $4.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $5.38M derived: sum of 2 quarters · filed 2022-11-09 | $5.82M 10-Q · filed 2022-11-09 | $5.86M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $672.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $1.11M 10-Q · filed 2022-08-09 | $1.16M derived: sum of 3 quarters · filed 2022-08-09 | $1.25M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $441.00K 10-Q · filed 2022-05-10 | $486.00K derived: sum of 2 quarters · filed 2022-05-10 | $576.00K derived: sum of 3 quarters · filed 2022-05-10 | $1.47M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $45.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $135.00K derived: sum of 2 quarters · filed 2022-03-01 | $1.02M derived: sum of 3 quarters · filed 2022-03-01 | $118.88M 10-K · filed 2022-03-01 |
| 2020-09-30 | $90.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-29 | $979.00K derived: sum of 2 quarters · filed 2021-10-29 | $118.83M 10-Q · filed 2021-10-29 | $118.30M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $889.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $118.74M 10-Q · filed 2021-08-06 | $118.21M derived: sum of 3 quarters · filed 2022-03-01 | $118.21M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $117.85M 10-Q · filed 2021-05-06 | $117.32M derived: sum of 2 quarters · filed 2022-03-01 | $117.32M derived: sum of 3 quarters · filed 2022-03-01 | $195.15M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | -$530.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$530.00K derived: sum of 2 quarters · filed 2022-03-01 | $77.30M derived: sum of 3 quarters · filed 2022-03-01 | $77.37M 10-K · filed 2022-03-01 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $77.83M derived: sum of 2 quarters · filed 2020-11-12 | $77.90M 10-Q · filed 2020-11-12 | $77.89M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $77.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $77.90M 10-Q · filed 2020-08-14 | $77.89M derived: sum of 3 quarters · filed 2021-03-01 | $77.89M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $64.00K 10-Q · filed 2020-05-12 | $54.00K derived: sum of 2 quarters · filed 2021-03-01 | $54.00K derived: sum of 3 quarters · filed 2021-03-01 | $75.75M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | -$10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$10.00K derived: sum of 2 quarters · filed 2021-03-01 | $75.69M derived: sum of 3 quarters · filed 2021-03-01 | $75.93M 10-K · filed 2021-03-01 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $75.70M derived: sum of 2 quarters · filed 2019-11-12 | $75.94M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $75.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $75.94M 10-Q · filed 2019-08-09 | ||
| 2018-03-31 | $238.00K 10-Q · filed 2019-06-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |